What is CYP3A4 in simple terms?

It is a liver enzyme that chemically modifies many of the compounds we consume orally, breaking them down or converting them into metabolites. CYP3A4 is the most prominent member of the cytochrome P450 enzyme family in human metabolism.

What does CYP3A4 do to mitragynine?

CYP3A4 oxidizes mitragynine at the 7-position of its indole ring system to produce 7-hydroxymitragynine. This is the principal metabolic route generating 7-OH in vivo following oral mitragynine consumption.

Where in the body is CYP3A4 active?

Primarily in the liver and the wall of the small intestine. Smaller amounts of CYP3A4 are expressed in other tissues.

Do CYP3A4 inhibitors affect 7-OH formation?

In published research models, yes. CYP3A4 inhibitors such as ketoconazole reduce the conversion of mitragynine to 7-OH. The clinical implications of these findings have not been established.

Does grapefruit juice inhibit CYP3A4?

Yes. Furanocoumarins in grapefruit juice are well-characterized intestinal CYP3A4 inhibitors. This is the basis for the long-standing instruction to avoid grapefruit juice when taking certain medications.

What other compounds besides mitragynine does CYP3A4 metabolize?

CYP3A4 is involved in the metabolism of more than half of all orally consumed compounds that undergo CYP metabolism, including many widely prescribed pharmaceuticals across cardiovascular, psychiatric, and analgesic categories.

Pharmacology Concepts

CYP3A4

At-a-glance comparison

Spec	Value
Full name	Cytochrome P450 Family 3 Subfamily A Member 4
Encoding gene	CYP3A4 (chromosome 7q22.1 in humans)
Enzyme class	Cytochrome P450 monooxygenase
Tissue expression	Highest in liver; significant in small intestine; minor in other tissues
Reaction catalyzed	Hydroxylation, dealkylation, and other oxidations of substrates
Kratom-relevant reaction	Oxidation of mitragynine to 7-hydroxymitragynine at the 7-position of the indole ring
Notable inhibitors	Ketoconazole, itraconazole, ritonavir, grapefruit juice (furanocoumarins)
Notable inducers	Rifampin, carbamazepine, phenytoin, St. John's wort

What is CYP3A4?

CYP3A4 is one of approximately 57 functional human cytochrome P450 enzymes - a large family of heme-containing monooxygenases that introduce oxygen atoms into organic substrates and are the principal mediators of phase-I drug metabolism. CYP3A4 is encoded by the CYP3A4 gene on chromosome 7 and is expressed at highest levels in the liver, with significant additional expression in the wall of the small intestine.

Among the human CYP enzymes, CYP3A4 has the broadest substrate specificity. It is estimated to participate in the metabolism of more than half of all orally consumed compounds that undergo CYP-mediated metabolism, including many widely prescribed pharmaceuticals. Its central role makes it the most-studied source of clinically meaningful drug-drug interactions.

How does CYP3A4 act on mitragynine?

When mitragynine is consumed orally - for example as kratom leaf, powder, or extract - it is absorbed across the intestinal wall and reaches the liver via the portal vein. In the liver, CYP3A4 catalyzes a hydroxylation reaction at the 7-position of mitragynine's indole ring system, producing 7-hydroxymitragynine. Smaller fractions of the dose are metabolized by other CYP enzymes and through phase-II conjugation, but CYP3A4 is the principal route generating 7-OH.

Because 7-OH binds the mu-opioid receptor with substantially higher affinity than mitragynine, the CYP3A4-mediated conversion is pharmacologically consequential: even a small fraction of orally consumed mitragynine converted to 7-OH contributes meaningfully to the in vivo pharmacology of kratom material. This is the mechanistic basis for describing 7-OH as the active metabolite of mitragynine.

CYP3A4 inhibitors and inducers

Many compounds modulate CYP3A4 activity. Inhibitors slow CYP3A4-mediated metabolism, increasing exposure to substrates and reducing exposure to active metabolites generated by the enzyme. Notable inhibitors include the antifungal ketoconazole and itraconazole, the protease inhibitor ritonavir, and the furanocoumarins in grapefruit juice. Inducers, by contrast, increase CYP3A4 activity over time and reduce substrate exposure while increasing metabolite formation. Notable inducers include the antibiotic rifampin, the anticonvulsants carbamazepine and phenytoin, and the herbal preparation St. John's wort.

In published research models of kratom alkaloid metabolism, CYP3A4 inhibitors reduce the conversion of mitragynine to 7-OH. The clinical implications of these in vitro and animal-model findings have not been established and are not the subject of this glossary entry.

Common questions about cyp3a4

What is CYP3A4 in simple terms?: It is a liver enzyme that chemically modifies many of the compounds we consume orally, breaking them down or converting them into metabolites. CYP3A4 is the most prominent member of the cytochrome P450 enzyme family in human metabolism.
What does CYP3A4 do to mitragynine?: CYP3A4 oxidizes mitragynine at the 7-position of its indole ring system to produce 7-hydroxymitragynine. This is the principal metabolic route generating 7-OH in vivo following oral mitragynine consumption.
Where in the body is CYP3A4 active?: Primarily in the liver and the wall of the small intestine. Smaller amounts of CYP3A4 are expressed in other tissues.
Do CYP3A4 inhibitors affect 7-OH formation?: In published research models, yes. CYP3A4 inhibitors such as ketoconazole reduce the conversion of mitragynine to 7-OH. The clinical implications of these findings have not been established.
Does grapefruit juice inhibit CYP3A4?: Yes. Furanocoumarins in grapefruit juice are well-characterized intestinal CYP3A4 inhibitors. This is the basis for the long-standing instruction to avoid grapefruit juice when taking certain medications.
What other compounds besides mitragynine does CYP3A4 metabolize?: CYP3A4 is involved in the metabolism of more than half of all orally consumed compounds that undergo CYP metabolism, including many widely prescribed pharmaceuticals across cardiovascular, psychiatric, and analgesic categories.

References

Kamble SH, Sharma A, King TI, et al. (2020). Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicology Letters.
Wilson LL, Harris HM, Eans SO, et al. (2020). Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug and Alcohol Dependence.
Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism. Pharmacology and Therapeutics.
U.S. Food and Drug Administration. (2020). Drug Interaction Studies - Cytochrome P450 Guidance for Industry.
Hassan Z, Muzaimi M, Navaratnam V, et al. (2013). From kratom to mitragynine and its derivatives. Neuroscience and Biobehavioral Reviews. PMID 23206666.

Important safety information:

Products containing 7-hydroxymitragynine (7-OH) are sold for adult use only (21+). These statements have not been evaluated by the U.S. Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. The FDA has raised safety concerns regarding concentrated 7-OH products; consult a qualified healthcare professional before use. Do not operate vehicles or machinery after use. Keep out of reach of children and pets. Laws vary by state, buyers are responsible for knowing applicable law.

Oops, your cart is still empty